Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration

A. M. Gori, G. Pepe, M. Attanasio, M. Falciani, R. Abbate, D. Prisco, S. Fedi, B. Giusti, T. Brunelli, P. Comeglio, G. F. Gensini, G. G. Neri Serneri

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Elevated plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) and large amounts of monocyte procoagulant activity (PCA) have been documented in unstable angina (UA) patients. In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. TF and TFPI plasma levels and monocyte PCA have been investigated in 28 refractory UA patients before and during anticoagulant subcutaneous heparin administration (thrice daily weight- and PTT-adjusted for 3 days) followed by 5000 IU x 3 for 5 days. After 2-day treatment, immediately prior to the heparin injection, TF and TFPI plasma levels [(median and range): 239 pg/ml, 130-385 pg/ml and 120 ng/ml, 80-287 ng/ml] were lower in comparison to baseline samples (254.5 pg/ml, 134.6-380 pg/ml and 135.5 ng/ml, 74-306 ng/ml). Four h after the heparin injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5%, p <0.001) and TFPI increased (240.5 ng/ml, 140-450 ng/ml; +67%, p <0.0001). After 7-day treatment, before the injection of heparin, TF and TFPI plasma levels (200 pg/ml, 128-325 pg/ml and 115 ng/ml, 70-252 ng/ml) significantly decreased (p <0.05) in comparison to the pre-treatment values. On the morning of the 8th day, 4 h after the injection of heparin TF plasma levels and monocytes PCA significantly decreased (156.5 pg/ml, 74-259 pg/ml and from 180 U/105 monocytes, 109-582 U/105 monocytes to 86.1 U/105 monocytes, 28-320 U/105 monocytes; -38% and -55% respectively) and TFPI increased (235.6 ng/ml, 152-423 ng/ml; +70%, p <0.001). In conclusion, heparin treatment is associated with a decrease of high TF plasma levels and monocyte procoagulant activity in UA patients. These actions of heparin may play a role in determining the antithrombotic and antiinflammatory properties of this drug.

Original languageEnglish
Pages (from-to)589-593
Number of pages5
JournalThrombosis and Haemostasis
Volume81
Issue number4
Publication statusPublished - 1999

Fingerprint

Thromboplastin
Heparin
Unstable Angina
Monocytes
Injections
lipoprotein-associated coagulation inhibitor
Therapeutics
Anticoagulants
Anti-Inflammatory Agents
Cytokines
Gene Expression
Weights and Measures
leukocyte procoagulant activity

ASJC Scopus subject areas

  • Hematology

Cite this

Gori, A. M., Pepe, G., Attanasio, M., Falciani, M., Abbate, R., Prisco, D., ... Neri Serneri, G. G. (1999). Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thrombosis and Haemostasis, 81(4), 589-593.

Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. / Gori, A. M.; Pepe, G.; Attanasio, M.; Falciani, M.; Abbate, R.; Prisco, D.; Fedi, S.; Giusti, B.; Brunelli, T.; Comeglio, P.; Gensini, G. F.; Neri Serneri, G. G.

In: Thrombosis and Haemostasis, Vol. 81, No. 4, 1999, p. 589-593.

Research output: Contribution to journalArticle

Gori, AM, Pepe, G, Attanasio, M, Falciani, M, Abbate, R, Prisco, D, Fedi, S, Giusti, B, Brunelli, T, Comeglio, P, Gensini, GF & Neri Serneri, GG 1999, 'Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration', Thrombosis and Haemostasis, vol. 81, no. 4, pp. 589-593.
Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thrombosis and Haemostasis. 1999;81(4):589-593.
Gori, A. M. ; Pepe, G. ; Attanasio, M. ; Falciani, M. ; Abbate, R. ; Prisco, D. ; Fedi, S. ; Giusti, B. ; Brunelli, T. ; Comeglio, P. ; Gensini, G. F. ; Neri Serneri, G. G. / Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. In: Thrombosis and Haemostasis. 1999 ; Vol. 81, No. 4. pp. 589-593.
@article{d108b98cf40948779898c6b1861c9621,
title = "Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration",
abstract = "Elevated plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) and large amounts of monocyte procoagulant activity (PCA) have been documented in unstable angina (UA) patients. In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. TF and TFPI plasma levels and monocyte PCA have been investigated in 28 refractory UA patients before and during anticoagulant subcutaneous heparin administration (thrice daily weight- and PTT-adjusted for 3 days) followed by 5000 IU x 3 for 5 days. After 2-day treatment, immediately prior to the heparin injection, TF and TFPI plasma levels [(median and range): 239 pg/ml, 130-385 pg/ml and 120 ng/ml, 80-287 ng/ml] were lower in comparison to baseline samples (254.5 pg/ml, 134.6-380 pg/ml and 135.5 ng/ml, 74-306 ng/ml). Four h after the heparin injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5{\%}, p <0.001) and TFPI increased (240.5 ng/ml, 140-450 ng/ml; +67{\%}, p <0.0001). After 7-day treatment, before the injection of heparin, TF and TFPI plasma levels (200 pg/ml, 128-325 pg/ml and 115 ng/ml, 70-252 ng/ml) significantly decreased (p <0.05) in comparison to the pre-treatment values. On the morning of the 8th day, 4 h after the injection of heparin TF plasma levels and monocytes PCA significantly decreased (156.5 pg/ml, 74-259 pg/ml and from 180 U/105 monocytes, 109-582 U/105 monocytes to 86.1 U/105 monocytes, 28-320 U/105 monocytes; -38{\%} and -55{\%} respectively) and TFPI increased (235.6 ng/ml, 152-423 ng/ml; +70{\%}, p <0.001). In conclusion, heparin treatment is associated with a decrease of high TF plasma levels and monocyte procoagulant activity in UA patients. These actions of heparin may play a role in determining the antithrombotic and antiinflammatory properties of this drug.",
author = "Gori, {A. M.} and G. Pepe and M. Attanasio and M. Falciani and R. Abbate and D. Prisco and S. Fedi and B. Giusti and T. Brunelli and P. Comeglio and Gensini, {G. F.} and {Neri Serneri}, {G. G.}",
year = "1999",
language = "English",
volume = "81",
pages = "589--593",
journal = "Thrombosis and Haemostasis",
issn = "0340-6245",
publisher = "Schattauer GmbH",
number = "4",

}

TY - JOUR

T1 - Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration

AU - Gori, A. M.

AU - Pepe, G.

AU - Attanasio, M.

AU - Falciani, M.

AU - Abbate, R.

AU - Prisco, D.

AU - Fedi, S.

AU - Giusti, B.

AU - Brunelli, T.

AU - Comeglio, P.

AU - Gensini, G. F.

AU - Neri Serneri, G. G.

PY - 1999

Y1 - 1999

N2 - Elevated plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) and large amounts of monocyte procoagulant activity (PCA) have been documented in unstable angina (UA) patients. In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. TF and TFPI plasma levels and monocyte PCA have been investigated in 28 refractory UA patients before and during anticoagulant subcutaneous heparin administration (thrice daily weight- and PTT-adjusted for 3 days) followed by 5000 IU x 3 for 5 days. After 2-day treatment, immediately prior to the heparin injection, TF and TFPI plasma levels [(median and range): 239 pg/ml, 130-385 pg/ml and 120 ng/ml, 80-287 ng/ml] were lower in comparison to baseline samples (254.5 pg/ml, 134.6-380 pg/ml and 135.5 ng/ml, 74-306 ng/ml). Four h after the heparin injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5%, p <0.001) and TFPI increased (240.5 ng/ml, 140-450 ng/ml; +67%, p <0.0001). After 7-day treatment, before the injection of heparin, TF and TFPI plasma levels (200 pg/ml, 128-325 pg/ml and 115 ng/ml, 70-252 ng/ml) significantly decreased (p <0.05) in comparison to the pre-treatment values. On the morning of the 8th day, 4 h after the injection of heparin TF plasma levels and monocytes PCA significantly decreased (156.5 pg/ml, 74-259 pg/ml and from 180 U/105 monocytes, 109-582 U/105 monocytes to 86.1 U/105 monocytes, 28-320 U/105 monocytes; -38% and -55% respectively) and TFPI increased (235.6 ng/ml, 152-423 ng/ml; +70%, p <0.001). In conclusion, heparin treatment is associated with a decrease of high TF plasma levels and monocyte procoagulant activity in UA patients. These actions of heparin may play a role in determining the antithrombotic and antiinflammatory properties of this drug.

AB - Elevated plasma levels of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) and large amounts of monocyte procoagulant activity (PCA) have been documented in unstable angina (UA) patients. In in vitro experiments heparin is able to blunt monocyte TF production by inhibiting TF and cytokine gene expression by stimulated cells and after in vivo administration it reduces adverse ischemic outcomes in UA patients. TF and TFPI plasma levels and monocyte PCA have been investigated in 28 refractory UA patients before and during anticoagulant subcutaneous heparin administration (thrice daily weight- and PTT-adjusted for 3 days) followed by 5000 IU x 3 for 5 days. After 2-day treatment, immediately prior to the heparin injection, TF and TFPI plasma levels [(median and range): 239 pg/ml, 130-385 pg/ml and 120 ng/ml, 80-287 ng/ml] were lower in comparison to baseline samples (254.5 pg/ml, 134.6-380 pg/ml and 135.5 ng/ml, 74-306 ng/ml). Four h after the heparin injection TF furtherly decreased (176.5 pg/ml, 87.5-321 pg/ml; -32.5%, p <0.001) and TFPI increased (240.5 ng/ml, 140-450 ng/ml; +67%, p <0.0001). After 7-day treatment, before the injection of heparin, TF and TFPI plasma levels (200 pg/ml, 128-325 pg/ml and 115 ng/ml, 70-252 ng/ml) significantly decreased (p <0.05) in comparison to the pre-treatment values. On the morning of the 8th day, 4 h after the injection of heparin TF plasma levels and monocytes PCA significantly decreased (156.5 pg/ml, 74-259 pg/ml and from 180 U/105 monocytes, 109-582 U/105 monocytes to 86.1 U/105 monocytes, 28-320 U/105 monocytes; -38% and -55% respectively) and TFPI increased (235.6 ng/ml, 152-423 ng/ml; +70%, p <0.001). In conclusion, heparin treatment is associated with a decrease of high TF plasma levels and monocyte procoagulant activity in UA patients. These actions of heparin may play a role in determining the antithrombotic and antiinflammatory properties of this drug.

UR - http://www.scopus.com/inward/record.url?scp=0032952131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032952131&partnerID=8YFLogxK

M3 - Article

C2 - 10235445

AN - SCOPUS:0032952131

VL - 81

SP - 589

EP - 593

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 4

ER -